Claims for Patent: 9,693,987

Summary for Patent: 9,693,987

Title:	Methods for treating cancers using oral formulations of cytidine analogs
Abstract:	Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents. Also provided are methods for using a cytidine analog, to treat diseases and disorders including disorders related to abnormal cell proliferation, hematologic disorders, and immune disorders, among others. In certain of the methods, the cytidine analog is formulated in an oral dosage form and administered orally.
Inventor(s):	MacBeth; Kyle J. (San Francisco, CA), Nguyen; Aaron N. (San Jose, CA), Dimartino; Jorge (Belmont, CA)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	14/688,623
Patent Claims:	1. A method for treating a subject having non-small cell lung cancer, wherein the method comprises orally administering to the subject a pharmaceutical composition comprising 5-azacytidine, or a pharmaceutically acceptable solvate or hydrate thereof and at least one pharmaceutically acceptable excipient, wherein the pharmaceutical composition comprising 5-azacytidine is a tablet; and the method further comprises administering at least one additional therapeutic agent comprising trastuzumab, rituximab, bevacizumab, pertuzumab, tositumomab, edrecolomab, G250, gemtuzumab ozogamicin, alemtuzumab, or yttrium-90-ibritumomab tiuxetan. 2. The method of claim 1, wherein the non-small cell lung cancer is a relapsed or refractory non-small cell lung cancer. 3. The method of claim 1, wherein the method comprises the steps of: (i) administering 5-azacytidine to the subject for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days; and (ii) administering the additional therapeutic agent to the subject for one or more days. 4. The method of claim 3, wherein the additional therapeutic agent is administered parenterally. 5. The method of claim 3, wherein the additional therapeutic agent is administered orally. 6. The method of claim 3, wherein step (ii) further comprises administering the 5-azacytidine orally for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days. 7. The method of claim 3, wherein the method comprises the sequential steps of: (i) administering 5-azacytidine to the subject for 7 days; (ii) administering the additional therapeutic agent to the subject for 1 day; (iii) administering 5-azacytidine to the subject for 6 days; and (iv) repeating steps (i) to (iii) after 7 days of resting period. 8. The method of claim 3, wherein the method comprises the sequential steps of: (i) administering 5-azacytidine to the subject for 7 days; (ii) administering 5-azacytidine and the additional therapeutic agent to the subject for 1 day; (iii) administering 5-azacytidine to the subject for 6 days; and (iv) repeating steps (i) to (iii) after 7 days of resting period. 9. The method of claim 3, wherein the method comprises the sequential steps of: (i) administering 5-azacytidine to the subject for 7 days; (ii) administering 5-azacytidine and the additional therapeutic agent to the subject for 1 day; (iii) administering 5-azacytidine to the subject for 6 days; (iv) administering the additional therapeutic agent to the subject for 1 day; and (v) repeating steps (i) to (iv) after 6 days of resting period. 10. The method of claim 3, wherein the method comprises the sequential steps of: (i) administering 5-azacytidine to the subject for 7 days; (ii) administering 5-azacytidine and the additional therapeutic agent to the subject for 1 day; (iii) administering 5-azacytidine to the subject for 6 days; (iv) administering the additional therapeutic agent to the subject for 1 day; (v) after 6 days of resting period, administering 5-azacytidine and the additional therapeutic agent to the subject for 1 day; (vi) administering 5-azacytidine to the subject for 6 days; and (vii) repeating steps (i) to (vi). 11. The method of claim 1, wherein the method comprises administering 5-azacytidine to the subject for at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7 days, before administering the additional therapeutic agent to the subject. 12. The method of claim 10, wherein the additional therapeutic agent is administered parenterally for one or more days. 13. The method of claim 10, wherein the additional therapeutic agent is administered orally for one or more days. 14. The method of claim 1, wherein the pharmaceutical composition comprises about 100 mg of 5-azacytidine. 15. The method of claim 1, wherein the pharmaceutical composition comprises about 200 mg of 5-azacytidine. 16. The method of claim 1, wherein the pharmaceutical composition comprises about 300 mg of 5-azacytidine. 17. The method of claim 1, wherein the subject is a human. 18. The method of claim 3, wherein the method comprises the sequential steps of: (i) administering 5-azacytidine and the additional therapeutic agent to the subject for 1 day; (ii) administering 5-azacytidine to the subject for 13 days; and (iii) repeating steps (i) and (ii) after 7 days of resting period. 19. The method of claim 3, wherein the method comprises the sequential steps of: (i) administering 5-azacytidine and the additional therapeutic agent to the subject for 1 day; (ii) administering 5-azacytidine to the subject for 20 days; and (iii) repeating steps (i) and (ii). 20. The method of claim 3, wherein the method comprises the sequential steps of: (i) administering 5-azacytidine and the additional therapeutic agent to the subject for 1 day; (ii) administering 5-azacytidine to the subject for 6 days; (iii) administering 5-azacytidine and the additional therapeutic agent to the subject for 1 day; (iv) administering 5-azacytidine to the subject for 6 days; (v) repeating steps (i) to (iv) after 7 days of resting period. 21. The method of claim 3, wherein the method comprises the sequential steps of: (i) administering 5-azacytidine and the additional therapeutic agent to the subject for 1 day; (ii) administering 5-azacytidine to the subject for 6 days; (iii) administering 5-azacytidine and the additional therapeutic agent to the subject for 1 day; (iv) administering 5-azacytidine to the subject for 13 days; (v) repeating steps (i) to (iv).

Details for Patent 9,693,987

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2031-11-01
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2031-11-01
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2031-11-01
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2031-11-01
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2031-11-01
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014		2031-11-01